Roxatat
Roxadustat
- 20 mg Tablet
- 50 mg Tablet
- 100 mg Tablet
Biotech and Oncology
Roxatat is a first-in-class, orally administered HIF-PH inhibitor that promotes erythropoiesis through increasing endogenous production of erythropoietin, as well as improving iron regulation and overcoming the EPO-suppressive effects of information on hemoglobin syntheses and red blood cell production by downregulating hepcidin.
